Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0021051 (immunodeficiency)
 71,517 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Since the clinician confronting a case of giardiasis may find the current literature confusing and weighted towards rare immunoglobulin deficiency syndromes, a classification is proposed to answer questions pertinent to understanding and managing this infection. Current thinking of giardiasis must involve the realization that (1) asymptomatic carriers exist; (2) that the majority of symptomatic patients have no structural disease explaining their symptoms; and (3) that those patients with anatomic lesions and giardiasis probably have an underlying predisposing condition. A short review of the association of giardiasis and immunodeficiency will then be presented, along with current concepts of diagnosis and therapy.
Am J Dig Dis 1976 Dec
PMID:Giardiasis: an overview for the clinician. 101 7

Cell-mediated immune response was investigated in fifteen patients with miliary tuberculosis. Delayed hypersensitivity skin test with "recall" antigens PPD and SKSD was positive in two and one patients respectively. An irritant dose of DNCB failed to induce non-specific inflammatory response in the skin of thirteen patients and the same patients also did not develop contact sensitivity to DNCB. Leucocyte migration test in the presence of Mycobacterium tuberculosis was also negative in eight of eleven patients studied. The proportion of E rosette-forming cells was found to be significantly depressed, though the proportion of EAC rosette-forming cells did not show any abnormality. On repeat skin tests in five patients after 3 months of chemotherapy and clinical improvement four showed a positive PPD and DNCB response. It was concluded that there is a marked degree of secondary immunodeficiency in miliary tuberculosis.
Clin Exp Immunol 1975 Dec
PMID:Secondary immunodeficiency in miliary tuberculosis. 108 82

Immunodeficiency functionally limited to the B-cell system together with mild hypothyroidism and severe growth hormone deficiency was found in a 6 1/2-month-old female infant with recurrent infections and growth retardation. A lymph node biopsy and post mortem examination of the lymphoid organs surprisingly revealed severe deficiency of both thymus-dependent and bursa-equivalent systems. The unusual combination of immune and endocrine deficiencies posed a difficult diagnostic problem. The hypothesis of an early-onset Louis-Bar syndrome was suggested and apparently corroborated by the autopsy findings of ovarian dysgenesis and cerebellar degeneration. The dissociation between functional and morphological findings as regards the immunodeficiency, and the possible links between immune and endocrine derangements are discussed.
Helv Paediatr Acta 1976 Dec
PMID:Unusual combination of immune and endocrine deficiencies. A possible case of early-onset Louis-Bar syndrome. 108 26

Quantitative in vivo migration of leukocytes into tissue has been analyzed by a new technique. This new method differs from previous methods by utilizing tape stripping of skin rather than skin abrasion, thereby preserving dermal vascular endothelium and the basal lamina of the epidermis. By preserving these two physiologic membranes, this technique simulates physiologic leukotaxis. Results in sixteen control patients revealed a mean of 1.12 X 10(6) leukocytes per chamber per 24 hours. In four patients with immunodeficiency this value was of 9.26 X 10(3) leukocytes per chamber per 24 hours clearly distinguishing this group from control groups (p less than 0.01). Reproducibility of duplicate chambers, simplicity, and comfort of the plastic chambers enhance its use by the clinical investigator as a secreening test for abnormalities in leukocyte movement.
J Lab Clin Med 1975 Dec
PMID:Leukocyte migration in vivo: a new method of study. 110 26

Host defense mechanisms were evaluated in a 4-1/2-year-old boy with recurrent pyogenic infections and a unique hyperkeratotic skin disorder. The patient's neutrophils were consistently defective in chemotactic responsiveness but had normal NBT reduction, glucose oxidation, and iodination. Serum concentrations of IgE were markedly elevated and the secondary antibody response was abnormal. No T-cell dysfunction was detected. These findings suggest a relationship between this patient and patients with other syndromes associated with recurrent infections, cutaneous disease, defective chemotaxis, immunodeficiency, and hyperimmunoglobulinemia E.
J Pediatr 1975 Dec
PMID:Defective neutrophil chemotaxis with variant ichthyosis, hyperimmunoglobulinemia E, and recurrent infections. 118 92

Fetal thymus transplantation was performed in three patients with thymic hypoplasia with abnormal immunoglobulin synthesis, one patient with ataxia telangiectasia, and one patient with immunodeficiency with eczema and thrombocytopenia. All patients received transfer factor before transplantation of a fetal thymus i.p. Reconstitution of cell-mediated immunity occurred in three of five patients. Two of the three patients with reconstitution of cell-mediated immunity also had evidence of improved antibody-mediated immunity. Reconstitution of cell-mediated immunity was characterized as occurring rapidly and being of varying duration, and was unassociated with HL-A chimerism. Successful reconstitution of immunity in these patients may have been related to several factors, including the use of fetal thymus less than 6 hr after abortion, i.p. transplantation, and a synergistic effect of transfer factor.
Transplantation 1975 Dec
PMID:Thymus transplantation in patients with thymic hypoplasia and abnormal immunoglobulin synthesis. 120 26

Skin sensitization with DNCB was carried out in forty-five untreated, 106 "on treatment" and fifteen fully treated patients with pulmonary tuberculosis along with fifty-five controls. Mantoux test with PPD was also carried out simultaneously. All the normal controls could be sensitized to DNCB and the degree of sensitization was 4+ in majority of the subjects. In contrast, in untreated patients only eighteen could be sensitized to DNCB and the degree of sensitivity did not reach 4+ in any patient. Similarly, fifty-five patients could not be sensitized with DNCB in the group of 106 subjects who were still suffering from active disease and were on therapy and none gave a 4+ response. The difference in the proportion of subjects who could be sensitized to DNCB in these two patient groups was significantly less in comparison to controls. Among fifteen patients who were fully treated and did not have active disease thirteeen could be sensitized with DNCB, but the degree of response was again found to be less than the controls. All the patients as well as the controls gave a high proportion of Mantoux positivity. These findings indicate that there is a subtle degree of immunodeficiency in pulmonary tuberculosis which improves simultaneously with the clinical improvement.
Clin Exp Immunol 1975 Dec
PMID:Dinitrochlorobenzene contact sensitization in pulmonary tuberculosis. 122 85

The skin response to 5 mug of purified phytohemagglutinin (PHA) was studied in 299 subjects, including 58 normal controls, 92 patients without malignancies, and 149 patients with nonlymphomatous cancer. Other immunological responses, such as in vitro lymphocyte stimulation (62 subjects) and skin response to purified protein derivatives (PPD) (95 subjects), were tested simultaneously to examine their correlation with the PHA skin test. A positive reaction was observed 24 hr after intradermal injection of 5 mug of purified PHA in 56 (96.6%) of 58 normal controls, 40 (49.4%) of 81 untreated patients with cancer, and 24 (35.3%) of 68 cancer patients receiving anticancer therapy. Among 32 patients with gastric cancer tested, impaired skin reactivity to purified PHA was noted in patients in stage III or IV. A correlation was found between in vivo and in vitro responses to PHA in 46 (74.2%) of 62 individuals (P less than 0.001). The PHA skin test was repeated 4 times over a period of three months in patients without malignancies, and no significant change in tehir skin reactivity was detected. In repeated tests, the skin reactivity to purified PHA of patients with lung cancer varied depending on the clinical status, and the extent and type of anticancer therapy the patients were receiving. It is concluded that the PHA skin test is a simple diagnostic method for screening for immunodeficiency in cancer patients before and during the course of anticancer therapy. Other advantages of this test are that no presensitization is required and that it can be used repeatedly.
Gan 1975 Dec
PMID:Phytohemagglutinin skin test: diagnostic value for showing immunodeficiency in patients with cancer. 122 17

Neutralizing antibodies that recognize the human immunodeficiency virus gp120 exterior envelope glycoprotein and are directed against either the third variable (V3) loop or conserved, discontinuous epitopes overlapping the CD4 binding region have been described. Here we report several observations that suggest a structural relationship between the V3 loop and amino acids in the fourth conserved (C4) gp120 region that constitute part of the CD4 binding site and the conserved neutralization epitopes. Treatment of the gp120 glycoprotein with ionic detergents resulted in a V3 loop-dependent masking of both linear C4 epitopes and discontinuous neutralization epitopes overlapping the CD4 binding site. Increased recognition of the native gp120 glycoprotein by an anti-V3 loop monoclonal antibody, 9284, resulted from from single amino acid changes either in the base of the V3 loop or in the gp120 C4 region. These amino acid changes also resulted in increased exposure of conserved epitopes overlapping the CD4 binding region. The replication-competent subset of these mutants exhibited increased sensitivity to neutralization by antibody 9284 and anti-CD4 binding site antibodies. The implied relationship of the V3 loop, which mediates post-receptor binding steps in virus entry, and components of the CD4 binding region may be important for the interaction of these functional gp120 domains and for the observed cooperativity of neutralizing antibodies directed against these regions.
J Virol 1992 Dec
PMID:Relationship of the human immunodeficiency virus type 1 gp120 third variable loop to a component of the CD4 binding site in the fourth conserved region. 127 95

We have used the technique of in vitro selection to generate variants of human immunodeficiency virus type 1 (HIV-1) that are resistant to 2',3'-dideoxyinosine (ddI) and cross-resistant to 2',3'-dideoxycytidine (ddC). The complete reverse transcriptase (RT)-coding regions, plus portions of flanking sequences, of viruses possessing a ddI-resistant phenotype were cloned and sequenced by polymerase chain reaction (PCR)-based methods. We observed that several of these viruses possessed mutations at amino acid sites 184 (Met-->Val; ATG-->GTG) and 294 (Pro-->Ser; CCA-->TCA). These mutations were introduced in the pol gene of infectious, cloned HXB2-D DNA by site-directed mutagenesis. Viral replication assays confirmed the importance of site 184 with regard to resistance to ddI. The recombinant viruses thus generated displayed more than fivefold-greater resistance to ddI than parental HXB2-D did. Moreover, more than fivefold-greater resistance to ddC was also documented; however, the recombinant viruses continued to be inhibited by zidovudine (AZT). No resistance to ddI, ddC, or AZT was introduced by inclusion of mutation site 294 in the pol gene of HXB2-D. PCR analysis performed on viral samples obtained from patients receiving long-term ddI therapy confirmed the presence of mutation site 184 in five of seven cases tested. In three of these five positive cases, the wild-type codon was also detected, indicating that mixtures of viral quasispecies were apparently present. Viruses possessing a ddI resistance phenotype were isolated from both subjects whose viruses contained only the mutated rather than wild-type codon at position 184 as well as from a third individual, whose viruses appeared to be mostly of the mutated variety.
J Virol 1992 Dec
PMID:Novel mutation in the human immunodeficiency virus type 1 reverse transcriptase gene that encodes cross-resistance to 2',3'-dideoxyinosine and 2',3'-dideoxycytidine. 127 98


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>